Leonard Valentino: Why Hemophilic Arthropathy Is More Than an Inflammatory Joint Disease
Leonard Valentino, President of WFH USA, shared a post on LinkedIn about a recent article he authored, published in Journal of Thrombosis and Haemostasis, adding:
“I’m excited to share my latest commentary in the Journal of Thrombosis and Haemostasis (JTH): ‘Hemophilic Arthropathy: When Shared Inflammatory Pathways Do Not Imply Shared Pathogenesis.’
For years, we’ve recognized that hemophilic arthropathy shares many inflammatory features with rheumatoid arthritis and osteoarthritis.
Similar cytokines, signaling pathways, synovial inflammation, and tissue remodeling can make these diseases appear biologically connected.
Yet an important question remains: do shared pathways necessarily mean shared mechanisms of disease?
In this commentary, I discuss emerging research suggesting that the answer may be no.
While inflammatory mediators may overlap across joint diseases, hemophilic arthropathy is fundamentally initiated by bleeding into the joint and the unique biological consequences of blood and iron exposure.
These distinct triggers may drive disease progression in ways that cannot be fully understood through comparisons with other arthritides alone.
As we pursue novel therapies to preserve joint health in people with hemophilia, understanding the difference between shared inflammatory signatures and true disease-driving mechanisms is critical.
The most effective treatments will likely come from targeting the pathways that are uniquely relevant to blood-induced joint disease.
I’m grateful to colleagues and investigators whose work continues to deepen our understanding of hemophilic arthropathy and challenge long-held assumptions about its pathogenesis.”
Title: Hemophilic arthropathy: when shared inflammatory pathways do not imply shared pathogenesis
Author: Leonard A. Valentino’

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian